30 Diabetes Drug Patents Expiring from 2024 till 2028 – GreyB
Given the competitive nature of the pharmaceutical domain, the expiration of drug patents presents significant opportunities, particularly for companies specializing in generic medications.
Pharmaceutical companies seeking to expand or diversify their generic drug portfolios would find this list of great value in identifying diabetes drug patents that will expire between 2024 and 2028. By utilizing this list, companies can develop their own generic versions of these drugs, which can then be marketed and sold at a lower cost than the brand-name versions. This process enables companies to reduce their reliance on a single drug or product and proactively manage risk by diversifying their drug portfolios.
In addition, the given list provides crucial insights such as the active ingredient, applicant, and route for generic drug manufacturers seeking to formulate a strategic entry into the diabetes treatment market. For instance, the route detail directs formulation strategies, ensuring that the generic versions are developed in line with the original drug’s delivery method for therapeutic equivalence.
While the aforementioned details are discussed in this article, the PDF version of “Diabetes Drug Patents Expiring from 2024 – 2028” can be obtained by filling out the form below.
DIABETES DRUG PATENTS EXPIRING FROM 2024 TO 2028
Admelog Solostar
Insulin Lispro
Applicant:
Sanofi-Aventis Us LLC.
| Patents | Expiration Date |
|---|---|
| US9011391 | 26-Mar-2024 |
| US9827379 | 4-Mar-2024 |
Apidra Solostar
Insulin Glulisine Recombinant
Applicant:
Sanofi-Aventis Us LLC.
| Patents | Expiration Date |
|---|---|
| US9011391 | 26-Mar-2024 |
| US9827379 | 2-Mar-2024 |
Bexagliflozin
Applicant:
Theracosbio LLC.
| Patents | Expiration Date |
|---|---|
| US8106021 | 22-Aug-2028 |
| US8802637 | 22-Aug-2028 |
Ingredients: Bexagliflozin
Route: Tablet;Oral
Exenatide Synthetic
Astrazeneca Ab
| Patents | Expiration Date |
|---|---|
| US9238076 | 15-Apr-2024 |
| US7612176 | 13-Apr-2025 |
| US8431685 | 13-Apr-2025 |
| US8461105 | 13-Apr-2025 |
| US7456254 | 30-Jun-2025 |
| US6515117 | 4-Oct-2025 |
| US8329648 | 18-Aug-2026 |
| US8906851 | 18-Aug-2026 |
| US9884092 | 18-Aug-2026 |
| US8501698 | 20-Jun-2027 |
| US8361972 | 21-Mar-2028 |
Ingredients: Exenatide Synthetic
Route: For Suspension, Extended Release;Subcutaneous
Exenatide Synthetic
Astrazeneca Ab
| Patents | Expiration Date |
|---|---|
| US9238076 | 15-Apr-2024 |
| US7612176 | 13-Apr-2025 |
| US8431685 | 13-Apr-2025 |
| US8461105 | 13-Apr-2025 |
| US7456254 | 30-Jun-2025 |
| US6515117 | 4-Oct-2025 |
| US8329648 | 18-Aug-2026 |
| US8906851 | 18-Aug-2026 |
| US9884092 | 18-Aug-2026 |
| US8501698 | 20-Jun-2027 |
| US8361972 | 21-Mar-2028 |
Ingredients: Exenatide Synthetic
Route: Suspension, Extended Release;Subcutaneous
Bydureon Pen
Exenatide Synthetic
Applicant:
Astrazeneca Ab
| Patents | Expiration Date | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ingredients: Exenatide Synthetic
Route: For Suspension, Extended Release;Subcutaneous
Farxiga
Dapagliflozin
Applicant:
Astrazeneca Ab
| Patents | Expiration Date | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ingredients: LUSUTROMBOPAG
Route: Dapagliflozin
Glyxambi
Empagliflozin; Linagliptin
Applicant:
Boehringer Ingelheim
| Patents | Expiration Date | ||||
|---|---|---|---|---|---|
|
|
Ingredients: Empagliflozin; Linagliptin
Route: Tablet; Oral
Inpefa
Sotagliflozin
Applicant:
Lexicon Pharmaceuticals Inc
| Patents | Expiration Date | ||||
|---|---|---|---|---|---|
|
|
Ingredients: Sotagliflozin
Route: Tablet;Oral
Invokamet
Canagliflozin; Metformin Hydrochloride
Applicant:
Janssen Pharmaceuticals Inc
| Patents | Expiration Date | ||||
|---|---|---|---|---|---|
|
|
Ingredients: Canagliflozin; Metformin Hydrochloride
Route: Tablet;Oral
Invokamet Xr
Canagliflozin; Metformin Hydrochloride
Applicant:
Janssen Pharmaceuticals Inc
| Patents | Expiration Date | ||||
|---|---|---|---|---|---|
|
|
Ingredients: Canagliflozin; Metformin Hydrochloride
Route: Tablet, Extended Release;Oral
Invokana
Canagliflozin
Applicant:
Janssen Pharmaceuticals Inc
| Patents | Expiration Date | ||||
|---|---|---|---|---|---|
|
|
Ingredients: Canagliflozin
Route: Tablet;Oral
Janumet
Metformin Hydrochloride; Sitagliptin Phosphate
Applicant:
Merck Sharp And Dohme LLC A Sub Of Merck & Co Inc
| Patents | Expiration Date | ||||
|---|---|---|---|---|---|
|
|
Ingredients: Metformin Hydrochloride; Sitagliptin Phosphate
Route: Tablet;Oral
Janumet Xr
Metformin Hydrochloride; Sitagliptin Phosphate
Applicant:
Merck Sharp And Dohme LLC A Sub Of Merck & Co Inc
| Patents | Expiration Date |
|---|---|
| US7326708 | 24-Nov-2026 |
Ingredients: Metformin Hydrochloride; Sitagliptin Phosphate
Route: Tablet, Extended Release;Oral
Januvia
Sitagliptin Phosphate
Applicant:
Merck Sharp And Dohme Corp
| Patents | Expiration Date |
|---|---|
| US7326708 | 24-Nov-2026 |
Ingredients: Sitagliptin Phosphate
Route: Tablet;Oral
Jentadueto
Linagliptin; Metformin Hydrochloride
Applicant:
Boehringer Ingelheim Pharmaceuticals Inc
| Patents | Expiration Date | ||||
|---|---|---|---|---|---|
|
|
Ingredients: Linagliptin; Metformin Hydrochloride
Route: Tablet;Oral
Jentadueto Xr
Sitagliptin Phosphate
Applicant:
Boehringer Ingelheim Pharmaceuticals Inc
| Patents | Expiration Date | ||||
|---|---|---|---|---|---|
|
|
Ingredients: Linagliptin; Metformin Hydrochloride
Route: Tablet, Extended Release;Oral
Juvisync
Simvastatin; Sitagliptin Phosphate
Applicant:
Merck Sharp And Dohme Corp
| Patents | Expiration Date |
|---|---|
| US7326708 | 11-Apr-2026 |
Ingredients: Simvastatin; Sitagliptin Phosphate
Route: Tablet;Oral
Lantus Solostar
Insulin Glargine Recombinant
Applicant:
Sanofi Aventis Us LLC
| Patents | Expiration Date | ||||
|---|---|---|---|---|---|
|
|
Ingredients: Insulin Glargine Recombinant
Route: Injectable;Injection
Ozempic
Semaglutide
Applicant:
Novo Nordisk Inc
| Patents | Expiration Date |
|---|---|
| US8536122 | 20-Mar-2026 |
Ingredients: Semaglutide
Route: Solution;Subcutaneous
Qtern
Dapagliflozin; Saxagliptin Hydrochloride
Applicant:
Astrazeneca Ab
| Patents | Expiration Date | ||||||
|---|---|---|---|---|---|---|---|
|
|
Ingredients: Dapagliflozin; Saxagliptin Hydrochloride
Route: Tablet;Oral
Qternmet Xr
Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride
Applicant:
Astrazeneca Ab
| Patents | Expiration Date | ||||
|---|---|---|---|---|---|
|
|
Ingredients: Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride
Route: Tablet, Extended Release;Oral
Rybelsus
Semaglutide
Applicant:
Novo Nordisk Inc
| Patents | Expiration Date |
|---|---|
| US8536122 | 20-Mar-2026 |
Ingredients: Semaglutide
Route: Tablet;Oral
Soliqua 100/33
Insulin Glargine; Lixisenatide
Applicant:
Sanofi-Aventis Us LLC
| Patents | Expiration Date | ||||
|---|---|---|---|---|---|
|
|
Ingredients: Insulin Glargine; Lixisenatide
Route: Solution;Subcutaneous
Steglujan
Ertugliflozin; Sitagliptin Phosphate
Applicant:
Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc
| Patents | Expiration Date |
|---|---|
| US7326708 | 24-Nov-2026 |
Ingredients: Ertugliflozin; Sitagliptin Phosphate
Route: Tablet;Oral
Toujeo Max Solostar
Insulin Glargine Recombinant
Applicant:
Sanofi Us Services Inc
| Patents | Expiration Date | ||||
|---|---|---|---|---|---|
|
|
Ingredients: Insulin Glargine Recombinant
Route: Solution;Subcutaneous
Toujeo Solostar
Insulin Glargine Recombinant
Applicant:
Sanofi Us Services Inc
| Patents | Expiration Date | ||||
|---|---|---|---|---|---|
|
|
Ingredients: Insulin Glargine Recombinant
Route: Solution;Subcutaneous
Tradjenta
Linagliptin
Applicant:
Boehringer Ingelheim Pharmaceuticals Inc
| Patents | Expiration Date | ||||
|---|---|---|---|---|---|
|
|
Ingredients: Linagliptin
Route: Tablet;Oral
Trijardy Xr
Empagliflozin; Linagliptin; Metformin Hydrochloride
Applicant:
Boehringer Ingelheim Pharmaceuticals Inc
| Patents | Expiration Date | ||||
|---|---|---|---|---|---|
|
|
Ingredients: Empagliflozin; Linagliptin; Metformin Hydrochloride
Route: Tablet, Extended Release;Oral
Xigduo Xr
Dapagliflozin; Metformin Hydrochloride
Applicant:
Astrazeneca Ab
| Patents | Expiration Date | ||||
|---|---|---|---|---|---|
|
|
Ingredients: Dapagliflozin; Metformin Hydrochloride
Route: Tablet, Extended Release;Oral
Conclusion
As diabetes drug patents expire, it expands the gateway for a number of competitors to enter the market. Tracking these patent expirations beforehand can not only help evaluate business opportunities but also help in refining market entry strategies.
But there still lies legal as well as technology threats and hurdles that a generic company will face depending on the drug they choose for the generic version.
With proper research and threat analysis, developing a generic version wouldn’t be as terrifying. How to go about it?
Well, let’s start with getting in touch by filling out the form below, and we’ll get back to you in no time.
Authored by: Annie Sharma, Editorial Team
Insights by: Nikhil Kaushal, Product Development Team
